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Editorial
Gregory Dolin*
The Short-Sighted Attack on Patent Eligibility of
Healthcare Related Patents
On March 20, 2012, the Supreme Court of the United States unanimously
decided the case of Mayo Collaborative Svc. v. Prometheus Labs. At issue
was a patent, held by Prometheus that taught doctors how to adjust the
amount of thiopurine (a drug used for treatment of a variety of autoimmune
diseases) administered to a patient. In an opinion by Justice Breyer, the Court
held Prometheus’s invention to not be patent eligible and invalidated the
patent. Though I believe that the reasoning the Court employed was erro
neous and highly problematic (of which more later), the decision could have
been viewed as a small problem if it were not part of a sustained, and
worldwide attack on the scope of patent eligibility for inventions in general
and heaithcare and biologic inventions in particular. This assault on the
availability of patents for inventions in some of the most complex and labor-
intensive areas of science bodes poorly for the future advances in these fields,
and therefore for the availabiliry of new breakthrough diagnostics and treat
ments fot the patients.
In Prometheus, the inventors discovered the (high) levels of thiopurine in the
body which would be toxic to the patient and the (low) levels which would
be ineffective for the treatment of the disease, and they patented a method
for the proper use of the drug which consisted of three steps: administering
the drug, measuring the level of the drug in the body, and then adjusting the
levels of the drug to get them within the therapeutic range. In striking down
the patent, the Supreme Court concluded that Prometheus was claiming a
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fair, no one disagreed with the proposition that the fact that thiopurine is
only effective at certain dosages and is toxic at higher levels is a “law of
nature.” But then again, that is not what the patent claimed. Instead, the
patent claimed an application of that law of nature to the treatment of
certain diseases. The Court did not consider this difference to be significant
as it concluded that the steps of administering drugs and ways of monitoring
their levels are well known. What is important to understand though, is that
the Court did not reject the patents for lack of novelty, but rather for failure
to claim patent-eligible subject matter. The problem with this approach is
that it melds together completely separate inquiries — that of the eligible
subject matter and that of novelty. The distinctness of these categories is
evident from the structure of the Patent Act, which has a separate section for
each requirement.
Not only did the Court misread the statute as a matter of statutory construc
don, but it effectively put into doubt all method-of-treatment patents. After
all, such patents all rely on laws of nature. The only reason certain drugs and
biologics work is because they exploit natural phenomena to achieve their
purpose. If that is the road that the Court intends to travel, then potential
profits from pharmaceutical research (and therefore incentive to conduct
such research) will be greatly diminished.
The Supreme Court expressed its belief that having a more stringent patent
eligibility requirement will likely benefit the public, because physicians will
be better able “to provide sound medical care.” This view, expressed by a
number of medical associations that have submitted briefs to the Court, has
been gaining currency not only in the U.S., but worldwide, reversing the
previous trend for a more inclusive patent eligibility regime. It is worth
remembering that for quite some time, patents on pharmaceutical com
pounds were not available in a number of countries, including developed
countries like Japan, Switzerland, Italy, Finland, Greece, Iceland, Monaco,
Norway, Portugal, and Spain. The reason behind this exclusion was the same
moral concern that animated the Prometheus Court, i.e., the availability of
needed drugs to the public. Yet, in the 30 years that the developed countries
have permitted patenting pharmaceuticals, we have developed more and
better drugs that have prolonged lives and alleviated suffering for countless
individuals. The fear that allowing exclusive rights to drugs will preclude
access has turned out to be unfounded. Yet, the Prometheus decision is just
one episode of the multi-front attack on pharmaceutical and biologic patents.
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Recently, litigants and activists in a number of countries have attacked
patents on DNA and other genetic materials. The American Civil Liberties
Union filed suit to declare DNA to be per se patent ineligible. Bills to
accomplish the same result have been introduced in Congress. Similar bills
have been introduced in Australia. European geneticists have issued similar
calls. Along the same lines, a number of countries simply disregard patent
rights by issuing compulsory licenses on valuable drugs. (A compulsory
license, after all, is little different from refusal to grant exclusive rights in the
El”:.
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first place). \Vhile that approach may be excused and even welcomed in the
face of a public health emergency, it is exceedingly hard to justify for drugs
like Viagra or Plavix. Yet countries have issued compulsory licenses for both
of those drugs.
All of these actions have popular appeal. The public prefers cheaper drugs
and tests to the more expensive ones. Thus udiciaI, executive, and legislative
actions that prevent anyone from charging monopoly rents by precluding the
availability of exclusive rights are likely to be met with cheers. However, this
is very shortsighted. Limiting of patent rights today may lower the cost and
increase availability of drugs and tests already on the market, but that
approach will also simultaneously lower incentives for further innovation.
Fewer treatments and diagnostics will be developed (and they will be devel
oped more slowly) as a result. In essence, limiting patent eligibility for
medical products benefits the present generation at the expense of the future
ones. If we are to hope that medicine will make as large strides in the next 30
years as it made in the past 30, courts, legislatures, and the public must be
convinced that limiting the scope of patent eligibility is precisely the wrong
way to go.
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A. Introduction
The principles concerning the liability of Internet intermediaries in Germany
are primarily based on case law. Specific and to some extent divergent
liability criteria have been developed not only within all concerned legal
areas but regarding almost all different types of service providers as well.
This makes it a demanding and challenging task for a legal practitioner to
acquire a general idea of the main liability conception on the one hand and
to stay well-informed and up-to-date with the new court practice tendencies
concerning all various legal aspects of the matter on the other. This article
aims to outline the main legal application areas of liability arising from the
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